Oracle announced Oracle Life Sciences AI Agents on November 18, 2026, and said they were available to early adopters that day. The agents are intended to support clinical-trial operations, starting with portfolio monitoring, trial planning and trial conduct, according to Oracle’s announcement.
What the agents are intended to do
Oracle says the agents draw on information from Oracle Life Sciences applications and supported third-party data sources. In the company’s example, an agent monitors a study’s performance, identifies likely drivers of changes in key performance indicators (KPIs), and recommends operational actions aligned with the trial protocol.
| Initial focus | Planned enhancements |
| Portfolio monitoring | Clinical data management |
| Trial planning | Post-trial analytics |
| Trial conduct | Trial design |
| Post-market workflows |
People approve proposed actions
Oracle says people review the agents’ recommendations and approve proposed actions before they are executed. The announced workflow therefore places the agents in a monitoring-and-recommendation role, with human approval before an operational response proceeds.
The approval step is central: the agents can recommend an operational response, but people review and approve it before execution.